Nu Eyne, a company specializing in electronic medicine and digital healthcare R&D, announced on the 4th that it has recently signed an exclusive supply contract worth USD $10M, strengthening its position in the global ADHD treatment market. This contract is the result of a strategic collaboration between Nu Eyne’s innovative electronic medicine technology and a global healthcare company, and is expected to be a significant turning point that will accelerate R&D and business expansion in domestic and overseas markets in the future.
ADHD (Attention Deficit Hyperactivity Disorder) affects more than 60 million people worldwide, and the number of ADHD patients in China alone is approximately 23 million. In particular, the Chinese ADHD treatment market is recording an average annual growth rate of more than 12% and is expected to expand to a scale of 5 billion dollars (USD $5B) by 2027. However, the current treatment market relies on drug therapy, and interest in alternative treatments is increasing due to concerns about side effects.
Nuine is providing an innovative ADHD treatment solution utilizing non-invasive trigeminal nerve electrical stimulation technology, and this contract provides an opportunity to reach more patients. Nuine has been conducting research and development on electronic drug-based ADHD treatment, and has been recognized for its technological prowess in the global market, including obtaining US FDA 510(k) approval.
Through this agreement, Newain plans to expand domestic and international clinical research, improve treatment opportunities and patient accessibility in the global market, and collaborate with medical experts and research institutions to optimize treatment protocols and strengthen data-based clinical research to verify treatment effects.
The electronic medicine market is growing at an average annual rate of more than 10% worldwide and is expected to grow to USD $35 billion by 2030. Nuain plans to establish itself as a leading company in the electronic medicine field through continuous investment in research and development and expansion of its global network.
Through this agreement, Newain aims to provide more effective and safer treatment options to global ADHD patients, and to this end, it plans to expand collaboration with various global medical networks. In addition, it plans to conduct joint research and clinical trials with domestic and international research institutes to further prove the treatment effectiveness.
Kim Do-hyung, CEO of Nuain, said, “This contract is a significant achievement that recognizes Nuain’s innovative electronic medicine technology in the global market,” and “We will do our best to provide effective treatment options to more patients through cooperation with our partners.”
- See more related articles
You must be logged in to post a comment.